VEGF / VEGFA / VEGF165 Neutralizing Antibody

1/1
Price:
Size:
Number:

VEGF / VEGFA / VEGF165 Neutralizing Antibody (Rabbit Monoclonal antibody) General Information

Product name
VEGF / VEGFA / VEGF165 Neutralizing Antibody
Validated applications
Neutralization
Species reactivity
Reacts with: Human
Specificity
Human VEGFA
Has cross-reactivity with mouse VEGF164 (Catalog # 50159-MNAB) and rat VEGF164 (Catalog # 80006-RNAB) in ELISA assay
Immunogen
Recombinant Human VEGF165/VEGFA protein (Catalog#11066-HNAB)
Preparation
This antibody was obtained from a rabbit immunized with purified, recombinant Human VEGF165/VEGFA (rh VEGF165/VEGFA; Catalog#11066-HNAB; P15692-4; Met1-Arg191) and was produced using recombinant antibody technology.
Source
Monoclonal Rabbit IgG Clone #R010
Purification
Protein A
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Endotoxin
Please contact us for more information.
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

VEGF / VEGFA / VEGF165 Neutralizing Antibody (Rabbit Monoclonal antibody) Validated Applications

Notes
Block: In a functional ELISA which immobilized recombinant Human VEGF165 (Catalog# 11066-HNAH) at 1 μg/mL (100 µL/well) in the plate, the Rabbit anti-Human VEGF165 Monoclonal Antibody can block the binding of 5 μg/mL of biotinylated recombinant Human VEGFR2 (Catalog# 10012-H08H-B) to human VEGF165,the EC50 is 1.51 μg/mL.
Neutralization: The neutralization activity of VEGF Neutralizing Antibody is measured by its ability to neutralize VEGF165 induced proliferation in HUVEC human umbilical vein endothelial cells. The VEGF Neutralization titer (IC50) is typically 5.35-21.4 ng/mL in the presence of 10 ng/mL Recombinant Human VEGF165 (11066-HNAB) .
Please Note: Optimal concentrations/dilutions should be determined by the end user.

VEGF / VEGFA / VEGF165 Neutralizing Antibody (Rabbit Monoclonal antibody) Images

Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 10-47 ng/mL in the presence of 10 ng/mL human VEGF165.

VEGF / VEGFA / VEGF165 Neutralizing Antibody: Alternative Names

Anti-MVCD1 Antibody; Anti-VEGF Antibody; Anti-VEGF165 Antibody; Anti-VPF Antibody

VEGFA Background Information

Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, inhibiting apoptosis and tumor growth. VEGF-A protein is also a vasodilator that increases microvascular permeability, thus it was originally referred to as vascular permeability factor.
Full Name
vascular endothelial growth factor A
References
  • Woolard J. et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64(21): 7822-7835.
  • Jia SF, et al. (2008) VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol. 7(2): 89-97.
  • Cimpean AM, et al. (2008) Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma. Rom J Morphol Embryol. 49(3): 303-8.
  • Hamdollah Zadeh MA, et al. (2008) VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation. 15(7): 605-14.
  • Eisenach PA, et al. (2010) MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci. 123(Pt 23):4182-4193.
  • Claesson-Welsh L (2010) Gremlin: vexing VEGF receptor agonist. Blood. 116(18):3386-7.

Standard Antibody Development Service

Rabbit MAb

Mouse MAb

Rabbit PAb

Fast Antibody Development Service

Mouse MAb

Rabbit PAb

Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait